Amir Hefni’s Post

We are delighted to announce that Resolution Therapeutics has received Medicines and Healthcare products Regulatory Agency approval to commence a Phase I/II EMERALD study for lead candidate RTX001, an engineered autologous macrophage cell therapy to treat end stage liver disease.   The study will investigate the safety and efficacy of RTX001 in patients with decompensated liver cirrhosis and is anticipated to start recruiting patients as early as Q3 2024. This #MHRA approval is the next step for Resolution becoming a fully clinical-stage biopharmaceutical company.   To learn more about Resolution and the development of macrophage cell therapies for end stage liver disease, join our R&D webinar TOMORROW at 12.30 BST / 7.30 EDT by registering through the link here: https://lnkd.in/ecTGYD-w   Read the full press release in the comments below.   #Macrophage #CellTherapy #ESLD

Do you know there are very limited treatment options for patients with inflammatory organ diseases? In this Sejelas CEO Interview series, we hear from Amir Hefni, the CEO of Resolution Therapeutics. The team is on a mission to transform the outcomes of patients with inflammatory organ disease by pioneering macrophage cell therapy. Read the full article here: https://lnkd.in/g_pm63se #biotech #ESLD #liver #therapeutics #sejelas #ceo #interviewseries

Resolution Therapeutics is excited to host an R&D webinar with a live Q&A on Friday 28th June at 12.30 BST / 7.30 EDT!   The management team will be joined by expert hepatologist, Arun Sanyal, M.D., and will provide an in-depth update on the extended MATCH Phase 2 clinical study as well as discuss Resolution’s innovative macrophage cell therapy platform following the teams’ presentations at this year’s #EASL2024 Annual Congress.   Register now and submit your questions in advance of the R&D webinar using the following link: https://lnkd.in/ecTGYD-w   See you there!   #ESLD #Macrophage #CellTherapy 

🌈 Happy Pride Month 🌈 At Resolution Therapeutics, we celebrate diversity and inclusivity. We are dedicated to supporting the LGBTQ+ community and creating a workplace where everyone feels valued, respected, and empowered to be their authentic selves. This year, the theme for LGBTQ+ history month was ‘Medicine under the scope’. During Pride Month, we honour the significant contributions of the LGBTQ+ community to advances in medical science. #PrideMonth #Diversity #LGBTQ #Equality

Join Resolution Therapeutics on June 28th 2024 at 12.30 BST / 7.30 EDT for an R&D webinar, featuring presentations from Resolution Therapeutics’ management team, alongside world leading hepatologist Arun Sanyal, M.D. This webinar follows Resolution Therapeutics' and The University of Edinburgh's clinical presentations at EASL | The Home of Hepatology's Congress 2024, where they provided updates on clinical data from the Extended MATCH Phase 2 study and insights into Resolution’s novel discovery platform. This event presents a fantastic opportunity to gather insights and pose questions directly to the Resolution team and an expert hepatologist regarding macrophage cell therapies to treat end-stage liver disease. Register using the link in the comments below! #ResolutionTherapeutics #EASL2024 #Macrophage #ESLD

Resolution Therapeutics today announces key data presentations with The University of Edinburgh at the EASL | The Home of Hepatology's Congress 2024, held in Milan, Italy. Presented in two posters, the data highlights the significant potential of macrophage cell therapy for advanced liver cirrhosis. The first poster reveals new data from the MATCH Phase 2 study, showing continued excellent safety and efficacy with autologous non-engineered macrophages, providing clear clinical proof of concept for this therapy as an effective and durable treatment for advanced liver cirrhosis. Resolution Therapeutics, holding exclusive rights to the technology and data has also developed a platform to engineer and cryopreserve autologous macrophages with a pro-regenerative phenotype for treating #ESLD. The second poster showcases an improved differentiation protocol and a more automated process to maximize manufacturing yields without compromising the phenotype. For more on the data presented at EASL, see the press release in the comments below. #Macrophage #EASLCongress #LiverDisease

End-stage liver disease is a cruel illness, compounded by the scarcity of donor livers needed to extend life. In the latest edition of #OptimumTV with Resolution Therapeutics’ CEO Amir Hefni, learn how the The University of Edinburgh spin-out is developing a pioneering non-surgical treatment for end-stage #liver disease using autologous cell therapy. #ResolutionTherapeutics #OptimumStrategicCommunications

Resolution Therapeutics today announces its attendance and scientific presentations at EASL | The Home of Hepatology Congress 2024, June 5th-8th, in Milan, Italy.   Join us and The University of Edinburgh for a series poster presentations showcasing extended follow up data from the MATCH Phase 2 study along with new data highlighting Resolution's discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use in patients with end-stage liver disease (#ESLD).   In addition to the poster presentations, Stuart Forbes, Ph.D., Professor of Transplantation and Regenerative Medicine at the The University of Edinburgh and co-founder of Resolution, will deliver a presentation titled “Macrophage therapy for liver disease” on Tuesday, June 4, 2024, at 5:00 p.m. CEST at the 3rd International Symposium on Regenerative Hepatology organized by the EASL Regenerative Hepatology Consortium in Milan, Italy.   For full details on the presentations, see the press release in the comments below.   #ResolutionTherapeutics #EASLCongress #LiverDisease #EASL2024

On June 4th, Resolution Therapeutics CEO Amir Hefni, and CFO Simon Ramsden will attend the Jefferies Global Healthcare Conference 2024 in New York. They will be meeting with investors to discuss their innovative macrophage cell therapies, aimed at transforming the treatment of inflammatory organ diseases. If you are attending and would like to learn more about Resolution Therapeutics or schedule a meeting, please get in touch! Full press release in the comments below. #ResolutionTherapeutics #JefferiesHealthcare #Macrophages